Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SpyGlass PharmaSGP -0.59%12 Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus rates SGP with a GF Score™ of 12/100. Among 968 Biotechnology companies, SpyGlass Pharma ranks better than 99.9% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for SpyGlass Pharma's Debt-to-Equity or its related term are showing as below:
SGP'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.06 Med: -0.03 Max: 0.01
Current: 0.01
During the past 3 years, the highest Debt-to-Equity Ratio of SpyGlass Pharma was 0.01. The lowest was -0.06. And the median was -0.03.
SGP's Debt-to-Equity is ranked better than 99.9% of 968
companies
in the Biotechnology industry
Industry Median: 0.16
vs SGP: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
SpyGlass Pharma Debt-to-Equity Related Terms
SpyGlass Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for SpyGlass Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SpyGlass Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SpyGlass Pharma Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SpyGlass Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where SpyGlass Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SpyGlass Pharma (SGP) has a Debt-to-Equity of 0.01 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SpyGlass Pharma and its competitors. According to the industry distribution chart, SpyGlass Pharma ranks #1 out of 968 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is SpyGlass Pharma's Debt-to-Equity too high?
SpyGlass Pharma's current Debt-to-Equity is 0.01. The Biotechnology industry median Debt-to-Equity is 0.16. SpyGlass Pharma's value of 0.01 is 93.8% below this industry median. Based on the distribution chart, SpyGlass Pharma ranks #1 out of 968 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's Debt-to-Equity compare to RIGL and NGNE?
According to the Biotechnology industry distribution chart, SpyGlass Pharma ranks #1 out of 968 companies for Debt-to-Equity. This places SpyGlass Pharma in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. SpyGlass Pharma's value of 0.01 is 93.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SpyGlass Pharma's current Debt-to-Equity of 0.01 is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SpyGlass Pharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SpyGlass Pharma's current Debt-to-Equity is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current Debt-to-Equity of 0.01. The current Debt-to-Equity is 0.01 and 93.8% below the Biotechnology industry median of 0.16. SpyGlass Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score
Get the complete analysis for SGP
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGP has been successfully added to your 
